Market Overview

Teva Offers Most Attractive Risk-Reward Profile, Citigroup Says

Related TEVA
UPDATE: Sterne Agee Upgrades Teva Pharmaceutical
Teva Pharmaceutical Releases 2015 Guidance, Sees Increased Generic Competition
Sofinnova Ventures Closes $500M Fund (Fox Business)

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are trading higher 1.5 percent to $49.86 after Citigroup added the stock to the U.S. focus list and raised the price target to $60 from $56.

Analyst Liav Abraham believes the shares offer the “most attractive risk-reward profile amongst multinational generics universe.”

The “resilience” of Teva's Copaxone, “commercial potential of the pipeline (particularly the respiratory and NTE portfolio), and optionality for increased net cost savings, as sufficient to drive further upside from current levels,” said Abraham.

The analyst's investment thesis is “not predicated on the need for M&A.”

Abrahams $60 price target is based on a “2015e earnings multiple of 13x, vs the peer group average of 13.6x.”

Latest Ratings for TEVA

DateFirmActionFromTo
Dec 2014Sterne AgeeUpgradesNeutralBuy
Dec 2014Deutsche BankMaintainsBuy
Dec 2014Bank of AmericaMaintainsBuy

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Citigroup Liav AbrahamAnalyst Color Analyst Ratings

 

Related Articles (TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters